Symptoms of Low Ginkgo Biloba: Causes and Treatment
Deficiency
Symptoms & causes
Ginkgo biloba is an herbal supplement, not a nutrient — no deficiency syndrome exists; despite being one of the world's most purchased supplements for memory and cognitive aging, the largest RCT ever conducted (GEM study) found no reduction in dementia or cognitive decline risk.
Ginkgo biloba is a botanical extract, not an essential nutrient, so the concept of a 'deficiency' has no clinical meaning. While it remains popular for memory and cognitive health, the landmark GEM study — the largest and most rigorous clinical trial ever conducted on ginkgo — found no benefit for preventing dementia or slowing cognitive decline. The supplement does carry real safety concerns, particularly its antiplatelet effects, which can increase bleeding risk when combined with blood thinners.
This is general nutrition and wellness information, not medical advice. If you're on a weight-loss medication or managing a health condition, confirm specifics with your clinician.
Symptoms of low Ginkgo biloba — extract from the leaves of the Ginkgo biloba tree, one of the oldest living tree species. Standardized extract (EGb 761 or LI 1370) contains two active compound classes: flavonol glycosides (approximately 24% — ginkgetin, bilobetin, quercetin, kaempferol, isorhamnetin derivatives) and terpene lactones (approximately 6% — ginkgolides A, B, C and bilobalide). Ginkgolide B is a potent platelet-activating factor antagonist, which is the basis for ginkgo's antiplatelet effect and the mechanism most linked to drug interactions. Bilobalide has neuroprotective properties in in vitro and animal models. Not a nutrient; no RDA, AI, or EAR established by NIH or IOM.
Everyday signs are on the left; the ones on the right mean it's time to check in with a clinician.
Everyday signs
Common symptoms
- Not applicable — botanical; no deficiency phenotype exists. Symptoms that drive searchers here: subjective memory complaints, cognitive decline concerns, tinnitus, peripheral vascular insufficiency (cold extremities, claudication), anxiety.
Don't wait
See a doctor if
- Memory decline or cognitive symptoms warrant clinical evaluation to rule out treatable causes (hypothyroidism, vitamin B12 deficiency, depression, medication side effects, sleep apnea, early neurodegenerative disease) before attributing them to 'low ginkgo.'
Who is most likely to run low
Some people are more prone to falling short than others — including many people on a weight-loss journey who are simply eating less.
- No deficiency population. Research populations: older adults with subjective memory complaints or mild cognitive impairment; patients with Alzheimer's disease; patients with peripheral arterial disease; patients with tinnitus; patients with anxiety disorders.
How low levels are diagnosed
No diagnostic test for ginkgo biloba insufficiency. Cognitive evaluation uses validated neuropsychological testing; tinnitus assessment is audiological; peripheral vascular disease is diagnosed via ABI (ankle-brachial index) and imaging.
How it's corrected
Most gaps close with food first, and supplementation when a clinician recommends it.
Not applicable for deficiency. Supplemental doses: standardized EGb 761 extract at 120 to 240 mg per day in divided doses is the dose range used in most clinical trials; products not standardized to this extract may differ significantly in composition and potency.
How to keep levels up
Not applicable.
When to see a clinician
Cognitive decline symptoms warrant proper evaluation before supplement use. Significant drug interactions require pharmacist or clinician review. Patients with epilepsy should avoid ginkgo (reported to lower seizure threshold). Avoid before surgery (antiplatelet effect).
Ginkgo Biloba for Memory: The GEM Study Result That Most Supplement Sites Ignore
If you've searched for ginkgo biloba and memory, you've almost certainly been told it 'supports brain health' or 'promotes cognitive function.' What you probably weren't told is that the largest, most rigorous clinical trial ever conducted on ginkgo found it does nothing to prevent dementia or slow cognitive decline.
The Ginkgo Evaluation of Memory (GEM) study enrolled 3,069 community-dwelling adults aged 75 and older with either normal cognition or mild cognitive impairment. Participants were randomized to receive either 240 mg per day of standardized EGb 761 ginkgo extract or a placebo, and they were followed for a median of approximately six years. The result, published in JAMA in 2008, was unambiguous: ginkgo did not reduce the incidence of dementia, including Alzheimer's disease, compared to placebo.
A companion trial conducted in France, the GuidAge study, similarly found no benefit for dementia prevention. These two large, long-term randomized controlled trials represent the highest quality evidence available, and both were negative. The smaller, shorter European trials that had previously suggested cognitive benefits lacked the statistical power and methodological rigor of the GEM study, which is why their positive findings have not held up under more rigorous scrutiny.
The National Center for Complementary and Integrative Health, the NIH's branch for evaluating supplements, currently states that there is insufficient evidence to support the use of ginkgo for preventing dementia or improving memory in healthy older adults. This is not a fringe position — it is the consensus of the best available data. Yet supplement marketing almost universally omits this finding, continuing to imply cognitive benefits that the evidence does not support.
Bottom line
The GEM study — the best-designed and largest RCT of ginkgo for dementia prevention — found no benefit. This single finding fundamentally limits the case for ginkgo as a cognitive supplement for healthy aging adults, regardless of what smaller trials showed.
What Ginkgo Might Actually Help With: Tinnitus, Anxiety, and Peripheral Circulation
While the cognitive-aging claims don't hold up to scrutiny, ginkgo does have a few use cases where the evidence, though not definitive, is more encouraging than for dementia. These are worth understanding if you're considering the supplement for reasons other than memory.
Tinnitus is the most commonly cited non-cognitive use in European clinical practice. A Cochrane review found insufficient evidence to draw a firm conclusion about ginkgo's effectiveness for tinnitus, but some individual trials and subgroup analyses have shown modest improvements for certain patients. The mechanism may involve improved cochlear blood flow and antioxidant protection of auditory hair cells, though this remains theoretical. If you're considering ginkgo for tinnitus, know that the evidence is mixed and a significant proportion of users will not experience benefit.
For peripheral arterial disease and claudication — the leg pain that occurs with walking due to narrowed arteries — the evidence is more consistent. Several European trials have demonstrated improvements in pain-free walking distance with ginkgo supplementation. This makes mechanistic sense: ginkgo's vasodilatory and antiplatelet effects, mediated largely by ginkgolide B's antagonism of platelet-activating factor, could improve microcirculation in ischemic tissue. This is arguably the most evidence-supported use of ginkgo.
Anxiety is an emerging area of interest. One well-designed randomized controlled trial in patients with generalized anxiety disorder found a significant reduction in anxiety symptoms with ginkgo compared to placebo. The study was modest in size, and the finding has not yet been replicated in a large confirmatory trial, so it should be viewed as preliminary. But it is more credible than the cognitive-aging claims because it comes from a properly controlled study in a defined clinical population.
Bottom line
The most consistent evidence for ginkgo is for peripheral arterial disease claudication and possibly tinnitus; the anxiety finding is interesting but from a single trial; the cognitive-aging claim is unsupported by the best evidence.
The Drug Interaction Risk: Anticoagulants, Antiplatelet Drugs, and Seizure Threshold
Ginkgo's most clinically important safety issue is not a matter of debate — it is a well-characterized pharmacological effect with real-world consequences. Ginkgolide B, one of the terpene lactones in standardized ginkgo extract, is a potent antagonist of platelet-activating factor. This means ginkgo inhibits platelet aggregation, effectively acting as a blood thinner.
When combined with medications that also affect clotting, the effect is additive and potentially dangerous. The list of interacting drugs is long and includes many commonly prescribed medications: warfarin, aspirin, clopidogrel, NSAIDs like ibuprofen and naproxen, and heparin. Case reports of spontaneous bleeding events, including subdural hematomas and intracranial hemorrhage, have been documented in patients taking ginkgo alongside these drugs. The standard clinical guidance is to discontinue ginkgo at least two weeks before any surgical procedure to reduce bleeding risk.
A less widely known but important safety concern involves seizures. Ginkgo seeds and, to a lesser extent, leaf extracts contain ginkgotoxin, a compound that antagonizes vitamin B6 and can lower the seizure threshold. For most people, the trace amounts in standardized extracts are unlikely to cause problems, but for individuals with epilepsy or a predisposition to seizures, the risk is real and the supplement should be avoided. This concern is almost never mentioned in consumer-facing supplement information.
There is also a theoretical risk of serotonin syndrome when ginkgo is combined with SSRIs or other serotonergic medications, based on proposed serotonergic effects of ginkgo constituents. The clinical evidence for this interaction is less robust than for the antiplatelet effect, but it warrants awareness and caution.
Bottom line
Ginkgo's antiplatelet effect is not theoretical — case reports of serious bleeding exist, and it must be discontinued pre-surgically and disclosed to all clinicians; the seizure-threshold concern is less common but relevant for patients with epilepsy.
How Ginkgo Works: Flavonoids, Terpenes, and the Proposed Neuroprotective Mechanisms
The disconnect between ginkgo's compelling biology and its disappointing clinical trial results is a textbook example of why mechanism does not equal efficacy. Understanding how ginkgo is supposed to work helps explain both its appeal and the limits of the evidence.
Standardized ginkgo extract, typically labeled as EGb 761, contains two main classes of active compounds. The flavonol glycoside fraction makes up roughly 24% of the extract and includes ginkgetin, bilobetin, quercetin, kaempferol, and isorhamnetin derivatives. These compounds are potent antioxidants that scavenge reactive oxygen species and may protect cell membranes from oxidative damage — a plausible mechanism for neuroprotection, given the role of oxidative stress in neurodegenerative disease.
The terpene lactone fraction comprises about 6% of the extract and contains the ginkgolides (A, B, and C) and bilobalide. Ginkgolide B is the most pharmacologically significant: it is a potent antagonist of platelet-activating factor, which explains ginkgo's antiplatelet and vasodilatory effects. Bilobalide has shown neuroprotective properties in laboratory studies, including mitochondrial protection, modulation of GABAergic neurotransmission, and reduction of ischemic brain damage in animal models.
This mechanistic picture is biologically plausible and well-characterized at the molecular level. The problem is that biological plausibility does not reliably predict clinical efficacy — a lesson that applies to many herbal supplements. The GEM study tested whether these mechanisms translate into real-world protection against cognitive decline, and the answer was no. The gap between the bench and the bedside is particularly wide for ginkgo, and it is a gap that supplement marketing routinely ignores.
Bottom line
The proposed neuroprotective mechanisms are biologically plausible and well-characterized at the molecular level — but biological plausibility does not equal clinical efficacy, as the GEM study demonstrated.
Ginkgo Biloba and GLP-1 Therapy: Cognitive Health, Vascular Overlap, and Drug Safety
People taking GLP-1 receptor agonists like semaglutide or tirzepatide often have metabolic syndrome with cardiovascular risk factors — hypertension, dyslipidemia, insulin resistance — that overlap with the conditions for which ginkgo has been studied. This creates both a rationale for interest and a specific safety concern that deserves attention.
The vascular overlap is real: the same atherosclerotic processes that GLP-1 drugs aim to mitigate through weight loss and metabolic improvement are the processes that cause peripheral arterial disease, one of ginkgo's more evidence-supported use cases. GLP-1 medications themselves have emerging data on cardiovascular protection and possible neuroprotection, though the cognitive data are preliminary. This might make ginkgo seem like a logical complement, but the drug interaction risk changes the calculus.
Many GLP-1 users are on low-dose aspirin for cardiovascular protection. Adding ginkgo on top of aspirin means stacking two antiplatelet agents — one pharmacologic, one herbal — with an additive effect on bleeding risk. This is not a theoretical concern; it is a direct consequence of ginkgolide B's mechanism. Anyone on aspirin, clopidogrel, or any other antiplatelet or anticoagulant medication should have a candid discussion with their pharmacist or clinician before adding ginkgo.
There is no known pharmacokinetic interaction between ginkgo's terpenes and flavonols and semaglutide or tirzepatide themselves. The concern is entirely about the antiplatelet effect and its interaction with other medications commonly prescribed to the same patient population. As always, full disclosure of all supplements to every treating clinician is essential — especially before any planned surgery or procedure.
Bottom line
GLP-1 users on aspirin for cardiovascular protection face the most relevant ginkgo safety concern — potentiated antiplatelet effect increasing bleeding risk; this warrants pharmacist review and disclosure to all treating clinicians before adding ginkgo.
What most pages leave out
The GEM study's null result for dementia prevention is the central honesty gap — virtually all supplement marketing for ginkgo continues to make cognitive health claims without disclosing that the best RCT found no benefit. The antiplatelet bleeding risk, with case reports of intracranial hemorrhage, is inconsistently disclosed. The seizure-threshold concern from ginkgotoxin is rarely mentioned. The 'anti-aging brain supplement' framing is arguably the most aggressively marketed and least evidentially supported position for any commonly purchased herbal supplement.
We flag this so you can make an informed choice — not to scare you off.
❓Frequently Asked Questions
There are none. Ginkgo biloba is not an essential nutrient, and the human body has no physiological requirement for its compounds. No clinical deficiency syndrome exists, so any symptoms attributed to 'low ginkgo' are actually signs of other conditions that warrant proper medical evaluation.
The best evidence says no. The GEM study, which followed over 3,000 older adults for approximately six years, found no reduction in dementia risk or cognitive decline with ginkgo compared to placebo. Smaller trials have shown mixed results, but the largest and most rigorous study was definitively negative.
Yes. Ginkgo inhibits platelet-activating factor and platelet aggregation, which can potentiate the effects of warfarin, aspirin, clopidogrel, and other blood-thinning medications. Case reports of spontaneous bleeding, including serious intracranial hemorrhage, have been documented in people taking ginkgo with these drugs.
The evidence is mixed. A Cochrane review found insufficient evidence to definitively conclude ginkgo is effective for tinnitus, though some individual trials and subgroup analyses have shown modest benefit for certain patients. It remains one of the more commonly studied uses outside of cognitive decline.
Clinical trials have typically used 120 to 240 mg per day of standardized EGb 761 extract, taken in divided doses. Products not standardized to this specific extract may differ significantly in composition and potency. Because of its antiplatelet effects, ginkgo should be discontinued at least two weeks before any scheduled surgery.
There is a plausible risk. Ginkgo contains trace amounts of ginkgotoxin, which can antagonize vitamin B6 and lower the seizure threshold. People with epilepsy or a history of seizures should avoid ginkgo for this reason.
It can be risky. The antiplatelet effect of ginkgo interacts with aspirin, warfarin, clopidogrel, and other cardiovascular medications that affect clotting. Anyone taking a blood-thinning drug should discuss ginkgo use with their pharmacist or prescribing clinician before starting it.
There is limited but intriguing evidence. One well-designed clinical trial found a significant reduction in anxiety symptoms among patients with generalized anxiety disorder taking ginkgo. This finding is more credible than the cognitive-aging claims but is based on a single study and needs replication.
Medically reviewed by
Chet Tharpe, MDBoard-certified physician
Last reviewed July 2026
Related Articles
What Are the Symptoms of Low Aloe Vera? Causes and Treatment
Aloe vera is a plant, not a nutrient—no deficiency exists. Learn the critical gel vs. latex safety distinction, FDA actions, and oral use risks for GLP-1 users.
Read moreSymptoms of Low Barley Grass: Why This Isn’t a Real Deficiency
Barley grass is a plant food, not an essential nutrient. There is no barley grass deficiency. Learn what it actually contains, what the weak evidence shows, and the real safety risks.
Read moreSymptoms of Low 5-HTP (5-Hydroxytryptophan): Causes & Treatment
5-HTP is a serotonin precursor, not a nutrient you can be deficient in. Learn what low serotonin activity means, the real risks of 5-HTP supplements, and safer alternatives.
Read moreSymptoms of Low Astaxanthin: Causes and Treatment
Astaxanthin is a powerful antioxidant found in salmon and shrimp, but there's no such thing as a deficiency. Learn what low intake actually means and what the science says.
Read moreSymptoms of Low Apple Cider Vinegar: Causes and Treatment
Apple cider vinegar is a condiment, not a nutrient — no deficiency syndrome exists. Learn what the research actually shows about ACV, blood sugar, and safety risks.
Read moreSymptoms of Low Ashwagandha: Causes and Treatment
Ashwagandha is an adaptogenic herb, not a nutrient. No deficiency syndrome exists. Learn what the evidence shows for stress, thyroid, and safety risks like thyrotoxicosis.
Read moreOn a GLP-1, or thinking about one?
Nutrient gaps are more common on a GLP-1 because you eat less — care that includes real clinical oversight helps you do it safely.Curex connects you with licensed clinicians for compounded GLP-1 medications, if it's right for you.
- Compounded semaglutide from $49/mo, tirzepatide from $149/mo
- Prescribed by licensed clinicians after an online visit
- Delivered to your door — no in-person clinic required
This content is for general informational purposes only and is not medical or nutritional advice, a diagnosis, or a substitute for professional judgment. It does not account for your health, medications, or goals, and nutrition information changes over time. Always talk with a qualified clinician or dietitian before making significant changes to your diet, supplements, or medications. Curex offers compounded GLP-1 medications through licensed clinicians and does not sell or endorse the food or supplement reviewed on this page.